Clinical applications

AI-assisted diagnosis for endoscopy centers and early cancer screening

yoyolink is co-developed with renowned Class-A tertiary hospitals in China and validated through multicenter clinical studies with 1000+ cases. The product holds an NMPA medical device registration certificate; multicenter validation continues to accumulate real cases, and multiple Shanghai hospitals are deploying the system in clinical practice.

Tertiary hospitals: AI-assisted reporting and QC statistics improve efficiency
Primary-level hospitals: real-time AI prompts raise early-cancer detection rates
Government screening programs: routine large-scale early GI cancer screening
Medical consortia: unified QC standards with traceable examination data

Book a demo Product overview

Clinical value

Higher early-cancer detection rates

Early GI cancer screening is a key strategy for reducing the incidence and mortality of gastric and colorectal cancer. yoyolink highlights suspected lesions in real time, acting as a “second pair of eyes” for physicians and raising the detection rate of early-stage cancer and other lesions in primary-level hospitals.

Greater examination efficiency

AI auto-captures screenshots, records insertion/withdrawal times, generates report drafts and compiles QC statistics — cutting repetitive documentation for tertiary hospitals.

Quality control that is measurable

Indicators such as examination completeness, Boston Bowel Preparation scores and lesion detection are aggregated into charts automatically, supporting continuous department improvement.

Traceable clinical data

Image-text information is traceable across the whole workflow, with examination, reporting and QC data managed in a closed loop to meet institutional quality and audit requirements.

Clinical track record

Data from clinical practice

1000+
Multicenter clinical validation cases: Multiple
Class-A tertiary hospital partners: 80+
Imaging feature types auto-annotated: 8–12
Images auto-selected per report

Use cases

Scenarios and institutions

From endoscopy centers to large-scale screening programs, yoyolink adapts to diverse clinical scenarios.

Hospital endoscopy centers

Improves examination efficiency and QC management while reducing documentation burden.

Gastroenterology / anorectal hospitals

Specialist institutions focused on digestive diseases benefit from AI-assisted lesion detection.

Professional physical examination centers

Fast, standardized reporting for screening endoscopy in physical exam populations.

Commercial health management centers

Standardized endoscopy and QC in premium health management settings.

Annual enterprise screening

Centralized annual GI endoscopy screening programs for enterprises and institutions.

Teaching hospitals and research institutions

Supports endoscopist training with AI annotation and QC data for education.

Government livelihood screening

A practical tool for large-scale government-funded early GI cancer screening.

High-incidence regions

Routine early cancer screening in regions with high gastrointestinal tumor incidence.

Medical consortia and paired assistance

Unified QC and reporting standards bring AI capability to primary care.

Journey

From co-development to clinical deployment

Co-development

Algorithms and clinical requirements refined together with renowned Class-A tertiary hospitals using real endoscopic imaging.
Innovative medical device pathway

Designated through the innovative medical device pathway with full-lifecycle management per medical device software standards.
Multicenter clinical validation

1000+ real clinical cases across multiple centers validated detection accuracy and clinical usability.
NMPA registration certificate obtained

The product holds an NMPA medical device registration certificate, qualified for hospital procurement and clinical use.
Shanghai hospital deployment

Multiple Shanghai hospitals have deployed the system in endoscopy centers and early cancer screening.

Clinical positioning statement

yoyolink displays suspected lesion regions in real time during endoscopy to provide assistive diagnostic reference for licensed endoscopists. Physicians make clinical decisions based on patient condition and actual imaging; the software is not a standalone basis for diagnosis.

Clinical Q&A

Clinical Q&A for patients and hospital staff

Common questions about clinical application, screening and the examination experience.

As a patient: will AI-assisted endoscopy take longer?

No. Real-time AI analysis does not add time to the procedure; automated screenshots, timing records and report drafts reduce the physician’s documentation work, making the overall flow smoother.

As a patient: what does an AI-suggested lesion mean?

AI prompts are references for the physician, not a final diagnosis. The physician makes the judgment based on the actual imaging and the patient’s condition, and may arrange further examination if needed.

As a patient: when will I receive my examination report?

The report is drafted with AI assistance and issued after physician review and confirmation, usually significantly faster than before; the exact time follows the hospital’s workflow.

As a physician: how does AI help raise early-cancer detection in primary-level hospitals?

Where endoscopic experience is more limited, real-time AI prompts for suspected lesions and site-coverage tracking help raise the detection rate of early-stage cancer and other lesions, while automated reporting reduces documentation burden.

As an endoscopy center manager: beyond examinations, what else can AI do for the department?

It automatically generates QC statistics and charts (volume, completeness, Boston scores, detection indicators) to support quality management, scheduling and continuous improvement.

As a hospital administrator: is it suitable for large-scale screening programs?

Yes. The system supports standardized batch workflows and automated QC statistics, suitable for government early-cancer screening initiatives, enterprise centralized screening, medical consortia and paired-assistance programs.